Ex Vivo Treatment of Murine Splenocyte-Supplemented Bone Marrow Inocula with Mafosfamide Prior to Allogeneic Transplantation in an Attempt to Prevent Lethal Graft-VERSUS-Host Disease without Compromising Engraftment

References

• Thomas E.D., Storb R., Clift R.A., et al. Bone marrow transplantation. N. Engl. J. Med. 1975; 292: 832
   PubMed Web of Science ®Google Scholar
• Storb R., Thomas E.D. Allogeneic bone-marrow-transplantation. Immunol. Rev. 1983; 71: 77
   PubMed Web of Science ®Google Scholar
• Tyan M.L. Modification of severe graft vs host disease with antisera to the theta antigen or to whole serum. Transplantation 1973; 15: 601
   PubMed Web of Science ®Google Scholar
• Neudorf S., Filipovich A., Ramsay N., Kersey J. Prevention and treatment of acute graft-versus-host disease. Semin. Hematol. 1984; 21: 91
   PubMed Web of Science ®Google Scholar
• Dicke K.A., van Hooft J.I.M., van Bekkum D.W. The selective elimination of immunologically competent cells from bone marrow and lymphatic cell mixtures. II. Mouse spleen cell fractionation on a discontinuous albumin gradient. Transplantation 1968; 6: 562
   PubMed Web of Science ®Google Scholar
• Korngold R., Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J. Exp. Med. 1978; 148: 1687
   PubMed Web of Science ®Google Scholar
• Vallera D.A., Soderling C.C.B., Carlson G.J., Kersey J.H. Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone. Transplantation 1981; 31: 218
   PubMed Web of Science ®Google Scholar
• Vallera D.A., Youle R.J., Neville D.M., Kersey J.H. Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin. J. Exp. Med. 1982; 155: 949
   PubMed Web of Science ®Google Scholar
• Mauch P., Lipton J.M., Hamilton B.L., Obbagy J., Nathan D., Hellman S. Reduction of lethal graft-versus-host disease: transplantation of cultured murine bone marrow across minor histocompatibility differences. Blood 1985; 66: 542
   PubMed Web of Science ®Google Scholar
• Epstein J., Bealmear P.M., Kennedy D.W., Herrmann M.J., Islam A., Wiedl S.C. Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2′-deoxycoformycin. Exp. Hematol. 1986; 14: 845
   PubMed Web of Science ®Google Scholar
• Filipovich A.H., Vallera D.A., Youle R.J., Neville D.M., Kersey J.H. Ex vivo T cell depletion with immunotoxins in allogeneic bone marrow transplantation: the pilot clinical study for prevention of graft-versus-host disease. Transpl. Proc. 1985; 17: 442
   Web of Science ®Google Scholar
• O'Reilly R.J., Collins N.H., Kernan N., et al. Transplantation of marrow-depleted T cells by soybean lectin agglutination and E-rosette depletion: major histocompatibility complex-related graft resistance in leukemic transplant recipients. Transpl. Proc. 1985; 17: 455
   Web of Science ®Google Scholar
• Mitsuyasu R.T., Champlin R.E., Ho W.G., et al. Prospective randomized controlled trial of ex vivo treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for prevention of graft-versus-host disease: a preliminary report. Transpl. Proc. 1985; 17: 482
   Web of Science ®Google Scholar
• Hervé P., Cahn J.Y., Flesch M., et al. Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement. Blood 1987; 69: 388
   PubMed Web of Science ®Google Scholar
• Kohn F.R., Sladek N.E. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochem. Pharmacol. 1985; 34: 3465
   PubMed Web of Science ®Google Scholar
• Kohn F.R., Sladek N.E. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557). Biochem. Pharmacol. 1987; 36: 2805
   PubMed Web of Science ®Google Scholar
• Smith P.C., Sladek N.E. Sensitivity of murine B-and T-lymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustards. Biochem. Pharmacol. 1985; 34: 3459
   PubMed Web of Science ®Google Scholar
• Shand F.L. The capacity of microsomally-activated cyclophosphamide to induce immunosuppression in vitro. Immunology 1978; 35: 1017
   PubMed Web of Science ®Google Scholar
• Sarpel S.C., Epstein R.B. Chemoseparation of cell populations in dogs by activated cyclophosphamide. Blood 1979; 54(suppl. 1)230a
   Google Scholar
• Körbling M., Hess A.D., Tutschka P.J., Kaizer H., Colvin M.O., Santos G.W. 4-Hydroperoxycyclophosphamide: a model for eliminating residual human tumour cells and T-lymphocytes from the bone marrow graft. Brit. J. Haematol. 1982; 52: 89
   PubMed Web of Science ®Google Scholar
• Gale R.P., Opelz G., Kiuchi M., Golde D.W. Thymus-dependent lymphocytes in human bone marrow. J. Clin. Invest. 1975; 56: 1491
   PubMed Web of Science ®Google Scholar
• Neudorf S., LeBien T., Bollum F., et al. Double fluorochrome analysis of human bone marrow lymphoid cells using terminal transferase and anti T cell monoclonal antibodies. Exp. Hematol. 1984; 12: 69
   PubMed Web of Science ®Google Scholar
• Ozer H., Cowen J.W., Colvin M., et al. In vitro effects of 4-hydro- peroxycyclophosphamide on human immunoregulatory T subset function. J. Exp. Med. 1982; 155: 276
   PubMed Web of Science ®Google Scholar
• Hill D.L., Laster W. R., Jr., Struck R.F. Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite. Cancer Res. 1972; 32: 658
   PubMed Web of Science ®Google Scholar
• Sladek N.E. Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res. 1973; 33: 1150
   PubMed Web of Science ®Google Scholar
• Cox P.J., Phillips B.J., Thomas P. The enzymatic basis of the selective action of cyclophosphamide. Cancer Res. 1975; 35: 3755
   PubMed Web of Science ®Google Scholar
• Domeyer B.E., Sladek N.E. Metabolism of 4-hydroxycyclophosphamide/aldophosphamide in vitro. Biochem. Pharmacol. 1980; 29: 2903
   PubMed Web of Science ®Google Scholar
• Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res. 1984; 44: 5156
   PubMed Web of Science ®Google Scholar
• Manthey C.L., Sladek N.E. Kinetic characterization of the catalysis of ‘activated’ cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases. Biochem. Pharmacol. 1988, in press
   PubMed Web of Science ®Google Scholar
• Kohn F.R., Landkamer G.J., Manthey C.L., Ramsay N.K.C., Sladek N.E. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines. Cancer Res. 1987; 47: 3180
   PubMed Web of Science ®Google Scholar
• Helander A., Tottmar O. Cellular distribution and properties of human blood aldehyde dehydrogenase. Alcoholism: Clin. Exp. Res. 1986; 10: 71
   PubMed Web of Science ®Google Scholar